The current standard-of-care imaging technique for the diagnosis of osteomyelitis is gadolinium-contrasted MRI (Gd-MRI).
1,2 However, Gd-MRI has imperfect specificity for osteomyelitis because signal enhancement also occurs in the presence of Charcot joints and other forms of sterile inflammation. 3, 4 The diagnosis of osteomyelitis has substantial clinical implications; there is a 15-25% lifetime risk of diabetic foot infections in diabetic patients. These infections are the basis for more than half of the nontraumatic lower extremity amputations performed. 2 Furthermore, the intravenous infusion of gadolinium salts in the presence of chronic kidney disease (CKD) can lead to incurable nephrogenic systemic fibrosis. 5 Recent research has suggested that superparamagnetic iron oxide nanoparticles (SPIONs) present an attractive alternative to gadolinium-based contrast agents for the MRI-aided diagnosis of inflammation and infection. SPIONs are taken up by macrophages and give rise to negative T 2 -weighted MRI contrast (darkening) in areas of inflammation. Preclinical and clinical studies suggest that iron oxide nanoparticle-contrasted MRI may be superior to gadolinium in distinguishing active osteomyelitis from other sterile forms of inflammation. 6, 7 Ferumoxytol is a SPION preparation that has been approved by the Food and Drug Administration in the United States for intravenous use as an iron replacement drug for patients with CKD. Unlike gadolinium-containing preparations, ferumoxytol may be safely used in patients who have kidney disease, a common comorbidity in diabetic patients with osteomyelitis. The purpose of this pilot study is to determine if ferumoxytol given to patients with clinically suspected osteomyelitis would cause negative T 2 -weighted MRI contrast changes.
Materials and Methods

Patients
This study was approved by the Institutional Review Board and complied with Health Insurance Portability and Accountability Act. Exclusion criteria included patients that were actively septic or clinically unstable, patients with a contraindication to MRI, patients with hemochromatosis, pregnant patients, and prisoners. Female patients with a hematocrit (HCT) > 48% and males with a HCT >52% were excluded.
Patient Monitoring
All patients were inpatients in this study. Patient's vital signs were monitored before, during, and for at least 24 h after the ferumoxytol infusion.
Imaging Protocol
MR images at 1.5 Tesla (T) were obtained at the inpatient MRI facility at the University of New Mexico Hospital with a Siemens Symphony instrument. Initial 192 3 256 pixel standard-of-care MR images included T 1 -weighted spin-echo (TR 5 347-520 ms; TE 5 10 ms) and T 2 -weighted STIR sequences (TR 5 3000-5660 ms; TE 5 34-57 ms). Gadopentetate dimeglumine (Magnevist, Bayer Health Care, Wayne, NJ) was used. Within 26-63 h after the standard-of-care MRI, patients received 7 mg/kg of intravenous (IV) ferumoxytol (Feraheme, AMAG Pharmaceuticals, Cambridge, MA), up to a maximum dose of 510 mg, as an infusion over 15 min. Ferumoxytol contrasted MRI was performed the day following ferumoxytol infusion (range, 14-25 h), and included a T Ã 2 GRE sequence. Interpretation of the images was performed subjectively by two radiologists (S.E. and G.M.) to determine the presence or absence of enhancement.
Histology of Resected Tissues
Bone biopsies and amputations were obtained as indicated by standard-of-care. CD68 is a surface marker for macrophages. CD68 stains used the Dako EnVision FLEX kit (Dako K8000) and the anti-CD68 antibody (Dako M0814) applied at a 1:2000 dilution for a 30-min incubation. Hemotoxylin and eosin slides were stained with Hematoxylin 2 (Richard-Allan Scientific ref. 
Results
The patients' demographics are shown in Table 1 . Patient 1 was a 69-year-old male with a history of type 2 diabetes complicated by peripheral neuropathy who presented with a nonhealing ulcer over the second distal phalanx. Our radiologists did not detect obvious pathologic enhancement using either gadolinium-or ferumoxytolcontrasted MRI (Fig. 1 ). An amputation was performed: histology ( Fig. 2A,D) showed no evidence of osteomyelitis nor macrophage infiltration.
Patient 2 was a 62-year-old male with a history of type 2 diabetes who presented with a purulent ulcer overlying the first distal phalanx. Positive enhancement was observed on T 1 -weighted sequences using gadolinium (Fig. 3B ) consistent with osteomyelitis. MR images taken after ferumoxytol administration demonstrated a negative enhancement (image darkening with contrast) on T 2 -weighted sequences (Fig. 3D) . The patient underwent toe ray amputation, and osteomyelitis was confirmed by histology (Fig.  2E) . The bone sample also showed macrophage invasion that was confirmed by CD68 immunohistochemistry (Fig. 2B, inset) . Culture of the osseous tissue was positive for enterococcus and candida (Table 2) .
Patient 3 was a 42-year-old male diagnosed with osteomyelitis of the fifth distal phalanx by the initial radiologist interpreting his standard-of-care MRI. Our study radiologists did not see The standard-of-care MRI was read as osteomyelitis of the second metatarsal extending into the proximal phalanx, including positive gadolinium enhancement on T 1 -weighted MR sequences (Fig. 4B) . Administration of ferumoxytol resulted in negative signal enhancement in the second metatarsal on T 2 -weighted sequences (Fig. 4D) . A toe ray amputation (Fig. 2F ). Excised bone culture was positive for methicillin-resistant staphylococcus aureus (MRSA: Table 2 ). None of the four patients developed sepsis within 24 h of ferumoxytol infusion, nor did they develop concerning vital sign changes or evidence of a hypersensitivity reaction.
Discussion/Conclusion
In this pilot study, negative enhancement on ferumoxytolcontrasted MRI correlated with macrophage infiltration and culture evidence of osteomyelitis. A possible weakness of our study is that there was some degree of variation between timing of ferumoxytol infusion and MRI. This was due to time limitations on the inpatient scanner. Future studies may include a time course to determine optimal imaging times. We believe that further studies are warranted to investigate the possibility of ferumoxytol-contrasted MRI for the diagnosis of osteomyelitis.
